ABSTRACT
BACKGROUND AND OBJECTIVES: According to current guidelines, oral antihistamines are the first-line treatment for chronic spontaneous urticaria (CSU). Up-dosing antihistamines to 4-fold the licensed dose is recommended if control is not achieved. Such indications are based mainly on expert opinion. Objectives: To critically review and analyze clinical evidence on the efficacy and safety of higher-than-licensed dosage of second-generation oral antihistamines in the treatment of CSU. MATERIAL AND METHODS: A systematic literature review was performed following a sensitive search strategy. All articles published in PubMed, EMBASE, and the Cochrane Library between 1961 and October 2018 were examined. Publications with CSU patients prescribed secondgeneration antihistamines in monotherapy compared with placebo, licensed dosages, and/or higher dosages were included. Articles were evaluated by peer reviewers. Quality was evaluated using the Jadad and Oxford scores. RESULTS: We identified 337 articles, of which 14 were included in the final evaluation (fexofenadine, 6; cetirizine, 2; levocetirizine and desloratadine, 1; levocetirizine, 1; rupatadine, 2; ebastine, 1; and bilastine, 1). Only 5 studies were placebo-controlled. The number of patients included ranged from 20 to 439. The observation lapse was ≤16 weeks. High fexofenadine doses produced a significant dosedependent response and controlled urticaria in most patients. Cetirizine, levocetirizine, rupatadine, and bilastine were more effective in up-dosing. The most frequent adverse events were headache and drowsiness. CONCLUSION: The low quality and heterogeneity of the articles reviewed made it impossible to reach robust conclusions and reveal the need for large-scale randomized clinical trials.
Subject(s)
Anti-Allergic Agents/therapeutic use , Chronic Urticaria/drug therapy , Histamine H1 Antagonists, Non-Sedating/therapeutic use , Administration, Oral , Animals , Clinical Trials as Topic , Drug Dosage Calculations , Drug-Related Side Effects and Adverse Reactions , Humans , Treatment OutcomeABSTRACT
Background: According to current guidelines, oral antihistamines are the first-line treatment for chronic spontaneous urticaria (CSU). Up-dosing antihistamines to 4-fold the licensed dose is recommended if control is not achieved. Such indications are based mainly on expert opinion. Objectives: To critically review and analyze clinical evidence on the efficacy and safety of higher-than-licensed dosage of second-generation oral antihistamines in the treatment of CSU. Material and Methods: A systematic literature review was performed following a sensitive search strategy. All articles published in PubMed, EMBASE, and the Cochrane Library between 1961 and October 2018 were examined. Publications with CSU patients prescribed secondgeneration antihistamines in monotherapy compared with placebo, licensed dosages, and/or higher dosages were included. Articles were evaluated by peer reviewers. Quality was evaluated using the Jadad and Oxford scores. Results: We identified 337 articles, of which 14 were included in the final evaluation (fexofenadine, 6; cetirizine, 2; levocetirizine and desloratadine, 1; levocetirizine, 1; rupatadine, 2; ebastine, 1; and bilastine, 1). Only 5 studies were placebo-controlled. The number of patients included ranged from 20 to 439. The observation lapse was ≤16 weeks. High fexofenadine doses produced a significant dosedependent response and controlled urticaria in most patients. Cetirizine, levocetirizine, rupatadine, and bilastine were more effective in up-dosing. The most frequent adverse events were headache and drowsiness. Conclusion: The low quality and heterogeneity of the articles reviewed made it impossible to reach robust conclusions and reveal the need for large-scale randomized clinical trials (AU)
Subject(s)
Humans , Anti-Allergic Agents/administration & dosage , Urticaria/drug therapy , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Administration, Oral , Chronic Disease , Clinical Trials as Topic , Drug Dosage Calculations , Drug-Related Side Effects and Adverse Reactions , Treatment OutcomeSubject(s)
Facial Neoplasms/pathology , Sarcoma/pathology , Skin Neoplasms/pathology , Aged, 80 and over , Humans , MaleABSTRACT
INTRODUCTION AND OBJECTIVES: The aim of this systematic review was to describe the incidence and mortality of basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma in Spain. MATERIAL AND METHODS: We performed a search of the MEDLINE and Embase databases and reviewed articles from the Spanish Network of Cancer Registries (REDECAN) and the International Agency for Research on Cancer (IARC). The methodological quality of the studies was evaluated and statistical heterogeneity was measured using the I(2) index. A random-effects model was used to perform the meta-analysis because of the heterogeneity of the data. RESULTS: Thirty-two papers were included in the systematic review. The crude incidence rate for basal cell carcinoma was 113.05 (95% CI, 89.03-137.08) cases per 100 000 person-years for the studies based on the registration methodology normally used by registries (in which only 1 tumor with histological confirmation is counted per person). However, the same incidence rate calculated on the basis of clinical and histologic criteria and counting tumors rather than individual patients was 253.23 (95% CI, 273.01-269.45) cases per 100 000 person-years. The incidence was 38.16 (95% CI, 31.72-39.97) cases per 100 000 person-years for squamous cell carcinoma, 8.76 (95% CI, 7.50-10.02) cases per 100 000 person-years for melanoma, and 0.28 (95% CI, 0.15-0.40) cases per 100 000 person-years for Merkel cell carcinoma. CONCLUSIONS: The registration methodology normally used by cancer registries probably underestimates the incidence rates of basal cell and squamous cell carcinoma in Spain. The incidence rates of cutaneous melanoma and Merkel cell carcinoma are lower in Spain than in other European countries.
Subject(s)
Skin Neoplasms/epidemiology , Carcinoma, Basal Cell/epidemiology , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Squamous Cell/epidemiology , Humans , Incidence , Melanoma/epidemiology , Skin Neoplasms/mortality , Spain/epidemiologyABSTRACT
The main objective of oncologic dermatologic surgery is the complete excision of skin tumors. During reconstruction of the defect, we must attempt to preserve function and cosmetic appearance. At the labial commissure, fibers from the superior and inferior portions of the orbicularis oris muscle intersect and the vermillion inserts onto the modiolus, a complex, cone-shaped structure at the angle of the mouth. Surgical reconstruction of the labial commissure is challenging because of the need to preserve sphincter function and cosmetic symmetry. We present a number of cases of surgical defects at the labial commissure and describe the reconstruction techniques used. We also propose an algorithm to help determine the most suitable technique for different cases.
Subject(s)
Carcinoma, Basal Cell/surgery , Carcinoma, Squamous Cell/surgery , Lip Neoplasms/surgery , Lip/surgery , Plastic Surgery Procedures/methods , Aged , Aged, 80 and over , Female , Humans , Male , Postoperative Complications/etiology , Surgical FlapsSubject(s)
Eosinophilia/etiology , Folliculitis/etiology , Lymphoma, T-Cell, Cutaneous/complications , Monoclonal Gammopathy of Undetermined Significance/complications , Skin Diseases, Vesiculobullous/etiology , Skin Neoplasms/complications , Bexarotene , CD3 Complex/analysis , CD4 Antigens/analysis , Eosinophilia/diagnosis , Eosinophilia/pathology , Folliculitis/diagnosis , Folliculitis/pathology , Humans , Interferon-alpha/therapeutic use , Lymphoma, T-Cell, Cutaneous/drug therapy , Male , Middle Aged , PUVA Therapy , Remission Induction , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/pathology , Skin Neoplasms/drug therapy , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/immunology , Tetrahydronaphthalenes/therapeutic useABSTRACT
The cheek is the largest anatomical subunit of the face. It is a bilateral structure and symmetry must therefore be preserved. Peripherally it is related to important natural orifices whose location must also be maintained during surgical reconstructions. This is particularly important in the medial zygomatic subunit, whose delicate junction with the lower eyelid means that care must be taken to avoid ectropion. We present 5 options for the reconstruction of surgical defects secondary to the excision of tumors in this region.
Subject(s)
Cheek/surgery , Facial Neoplasms/surgery , Aged , Female , Humans , Male , Plastic Surgery Procedures/methodsABSTRACT
The subcutaneous pedicled V-Y advancement flap is useful for the repair of small and medium-sized defects in areas where it is easy to obtain a good subcutaneous pedicle (upper lip, cheek, eyebrow, and nasal tip and ala). The almost complete absence of subcutaneous tissue on the anterior aspect of the auricle of the ear can limit the use of this approach in this region. We present 4 patients in whom subcutaneous pedicled V-Y advancement flaps were used to repair surgical defects of the helix, scaphoid fossa, and antitragus, achieving a good functional and aesthetic result in all cases.
Subject(s)
Ear Auricle/surgery , Surgical Flaps , Humans , Plastic Surgery Procedures/methods , Subcutaneous Tissue/transplantationSubject(s)
Mycosis Fungoides/pathology , Skin Neoplasms/pathology , Aged , Female , Humans , Male , Middle AgedABSTRACT
Acute generalized exanthematous pustulosis (AGEP) is a rare, severe, pustular, cutaneous reaction. We report a case in which a patient developed AGEP after the intake of 3 different antitussive agents containing dextromethorphan as the only ingredient in common.